ALKS vs INDV: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: INDV is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALKS and INDV share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALKS and INDV exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Alkermes plc is an Ireland-domiciled, Nasdaq-listed biopharmaceutical company focused on the central nervous system. Its commercial base spans Vivitrol (extended-release naltrexone for alcohol and opioid dependence), Aristada (long-acting injectable for schizophrenia), and Lybalvi (an oral olanzapine/samidorphan combination for schizophrenia and bipolar I). In February 2026 it acquired Avadel Pharmaceuticals, adding Lumryz, a once-nightly sodium oxybate for narcolepsy, which broadened the portfolio into sleep medicine. The company is profitable on an adjusted basis and generates meaningful operating cash flow, which it uses to fund its pipeline rather than relying heavily on dilution.

Full ALKS guide

Indivior is a specialty pharmaceutical company that develops and markets treatments for opioid use disorder (OUD) and related conditions. Its flagship product, SUBLOCADE, is a once-monthly long-acting injectable form of buprenorphine that has become the dominant long-acting injectable (LAI) for OUD in the United States, holding roughly a 76% share of that market. The company also sells the sublingual film SUBOXONE (now facing generic competition), the opioid overdose reversal agent OPVEE (nalmefene nasal spray), and PERSERIS for schizophrenia. Indivior historically listed in London but shifted its primary listing to the Nasdaq, and it trades under the ticker INDV.

Full INDV guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ALKS drivers: Orexin pipeline optionality; Cash-generative commercial base.
• INDV drivers: SUBLOCADE market leadership and expansion; Margin expansion and cash generation.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Clinical outcomes are binary: a Phase 3 setback for alixorexton would remove the main growth thesis and could sharply reset the valuation. For INDV, indivior is highly concentrated in a single product, so any slowdown in SUBLOCADE adoption, pricing pressure, or competitive entry (for example from Alkermes VIVITROL or Camurus and Braeburn's BRIXADI) would weigh heavily on the whole company.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALKS if you believe its drivers more; INDV if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALKS and INDV guides.

ALKS. First-quarter 2026 revenue of roughly $393 million rose about 28% year over year, helped by product growth and the newly consolidated Lumryz, though the quarter showed a GAAP net loss partly reflecting Avadel deal costs. Adjusted EBITDA of around $80 million underscores the underlying profitability of the marketed portfolio. At an approximately $8.5 billion market cap on roughly $1.5 billion of trailing revenue, the market is pricing in meaningful pipeline value beyond the current product base.

INDV. Indivior trades as a profitable mid-cap specialty pharma, with a price-to-sales multiple around 4x on roughly $1.2 billion of trailing revenue. The valuation embeds expectations that SUBLOCADE keeps compounding and that margins stay above 50%. Because one product drives most revenue, the multiple is sensitive to any change in SUBLOCADE's growth trajectory.

Headline figures (approximate, July 2026): ALKS shows revenue (ttm) ~$1.5B, q1 2026 revenue ~$393M (+28% YoY), q1 2026 adj. ebitda ~$80M, q1 2026 gaap net loss ~$(67)M; INDV shows revenue (ttm) ~$1.2B, 2026 revenue guidance ~$1.215B to $1.285B, sublocade q1 2026 net revenue ~$232M (up ~32% YoY), adjusted ebitda (2026 guide) ~$620M to $660M.

ALKS and INDV are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALKS and INDV exposure against your real portfolio. It is not an investment adviser.